Page last updated: 2024-09-04

gadolinium dtpa and Esophageal Squamous Cell Carcinoma

gadolinium dtpa has been researched along with Esophageal Squamous Cell Carcinoma in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's2 (66.67)2.80

Authors

AuthorsStudies
Ge, XL; Liu, XS; Sun, NN; Xu, LL1
Ge, X; Liu, X; Sun, N; Xu, L1
Hou, J; Li, FP; Lu, Q; Tang, J; Wang, H; Wang, LL; Yu, XP1

Other Studies

3 other study(ies) available for gadolinium dtpa and Esophageal Squamous Cell Carcinoma

ArticleYear
Histogram analysis of DCE-MRI for chemoradiotherapy response evaluation in locally advanced esophageal squamous cell carcinoma.
    La Radiologia medica, 2020, Volume: 125, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Contrast Media; Esophageal Squamous Cell Carcinoma; Female; Gadolinium DTPA; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Retrospective Studies

2020
Dynamic contrast-enhanced MRI histogram parameters predict progression-free survival in patients with advanced esophageal squamous carcinoma receiving concurrent chemoradiotherapy.
    Acta radiologica (Stockholm, Sweden : 1987), 2020, Volume: 61, Issue:10

    Topics: Aged; Chemoradiotherapy; Contrast Media; Esophageal Squamous Cell Carcinoma; Female; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Male; Neoplasm Staging; Progression-Free Survival; Radiotherapy Dosage; Retrospective Studies

2020
Utility of intravoxel incoherent motion diffusion-weighted imaging in predicting early response to concurrent chemoradiotherapy in oesophageal squamous cell carcinoma.
    Clinical radiology, 2018, Volume: 73, Issue:8

    Topics: Chemoradiotherapy; Contrast Media; Diffusion Magnetic Resonance Imaging; Esophageal Squamous Cell Carcinoma; Female; Gadolinium DTPA; Humans; Image Interpretation, Computer-Assisted; Male; Middle Aged; Predictive Value of Tests; Treatment Outcome

2018